Page 215 - 110413CHI_BR_DF_JB_ID11494_FinalCut_ABC_send_15_WEBblaetter_kl

215 Jahresbericht 2008 – 2009

94. Kolb A, Kleeff J, Fröhlich B, Werner J, Friess H, Büchler MW: Resection of the intrapan-creatic bile duct preserving the pancreas. J Hepato-biliary Pan. 16(1):31-4

95. Kolb A, Rieder S, Born D, Giese NA, Giese T, Rudofsky G, Werner J, Büchler MW, Friess H, Esposito I, Kleeff J: Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus. Cancer Biol Ther. 8(16): 1527-33

96. Köninger J, Wente MN, Müller-Stich BP, di Mola FF, Gutt CN, Hinz U, Müller MW, Friess H, Büchler MW: R2 resection in pancreatic cancer--does it make sense?. Langenbeck Arch Surg. 393(6):929-34

97. Kotelis D, Geisbüsch P, Hinz U, Hyhlik-Dürr A, Tengg-Kobligk HV, Allenberg JR, Böckler D: Short- and midterm results after left sub-clavian ar tery coverage during endovascu-lar repair of the thoracic aorta. J Vasc Surg. 50(6):1285-92:

98. Kremer T, Hernekamp F, Riedel K, Peter C, Gebhardt MM, Germann G, Heitmann C, Walther A: Topical application of cerium ni-trate prevents burn edema after burn plasma transfer. Microvasc Res. 78(3):425-31 99. Kulu Y, Schmied BM, Werner J, Muselli P, Büchler MW, Schmidt J: Total pancreatectomy for pancreatic cancer: indications and opera-tive technique. HPB (Oxford). 11(6):469-75 100. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K: Prognostic significance of hi-stopathological tumor regression after neo-adjuvant chemotherapy in esophageal aden-ocarcinomas. Modern Pathol. 22(12):1555-63 101. Lehner t T, Cardona S, Hinz U, Willeke F, Mechtersheimer G, Treiber M, Herfarth C, Buechler MW, Schwarzbach MH: Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. EJSO-Eur J Surg Oncol. 35(9):986-93

102. Li Z, Nickkholgh A, Yi X, Bruns H, Gross ML, Hoffmann K, Mohr E, Zorn M, Büchler MW, Schemmer P: Melatonin protects kid-ney grafts from ischemia/reperfusion injury through inhibition of NF-kB and apoptosis after experimental kidney transplantation. J Pineal Res. 46(4):365-72

103. Liang R, Bruns H, Kincius M, Lin T, Ludwig J, Dei-Anane G, Guan X, Gebhard MM, Büchler MW, Schemmer P: Danshen protects liver graf ts from ischemia/reperfusion injury in

experimental liver transplantation in rats. Transpl Int. 22(11):1100-9:

104. Liang R, Nickkholgh A, Hoffmann K, Kern M, Schneider H, Sobirey M, Zorn M, Büchler MW, Schemmer P: Melatonin protects from hepatic reperfusion injury through inhibition of IKK and INK pathways and modification of cell proliferation. J Pineal Res. 46(1):8-14 105. Löffler T, Welsch T, Mühl S, Hinz U, Schmidt J, Kienle P: Long-term success rate after sur-gical treatment of anorectal and rectovaginal fistulas in Crohn’s disease. Int J Colorectal Dis. 24(5):521-6

106. Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H: Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer. 26:9:463

107. Lordick F, Ott K: Neoadjuvante und adjuvante Therapie des Magen- und Ösophaguskarzi-noms. Gastroenterologe. 4:224-231

108. Lordick F, Ott K, Werner J, Weitz J, Jäger D: Multimodale Therapie des Magenkarzinoms. Fokus Onkologie. 12:14-21

109. Lorenzen S, Ott K, Lordick F: Multimodale Therapie bei Karzinomen des gastroösopha-gealen Übergangs (GÖÜ). Onkopipeline. 2(3) 92-100

110. Märten A, Schmidt J, Ose J, Harig S, Abel U, Münter MW, Jäger D, Friess H, Mayerle J, Ad-ler G, Seufferlein T, Gress T, Schmid R, Büch-ler MW: A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment and Cisplatin (CapRI) or Radiati-on alone regarding Event-Free Survival - Ca-pRI-2. BMC Cancer. 9(1):160:

111. Märten A, Wente MN, Ose J, Büchler MW, Rötzer I, Decker-Baumann C, Karapanagio-tou-Schenkel I, Harig S, Schmidt J, Jäger D: An open label randomized multicentre pha-se IIIb trial comparing parenteral substituti-on versus best supportive nutritional care in subjects with pancreatic adenocarcinoma re-ceiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO. BMC Cancer. 27:9:412

112. McArthur N, Kasperk C, Baier M, Tanner M, Gritzbach B, Schoierer O, Rothfischer W, Krohmer G, Hillmeier J, Kock HJ, Meeder PJ,